# Phase 6 Critique — Selank (iteration 2, post-fix)

Independent red-team re-critique of the Selank report after the §4 citation-precision fix, bar 92, genuine defects only.

## §4 re-anchor — RESOLVED (was the sole iteration-1 minor finding)
The iteration-1 minor finding (citation-incomplete) flagged that the §4 "Defining safety fact" sentence (line 155) anchored the full benzodiazepine-liability-absence list to [10][12][16], where [16] (Volkova et al. 2016, *Front Pharmacol*) is a Wistar-rat GABAergic gene-expression study — a mechanistic/preclinical source, not a clinical tolerability primary. The fix re-anchors that human tolerability claim to the clinical trials [10][12][11], explicitly naming the Medvedev 2015 UKU-tolerability study [11] as the instrument-anchored support that directly measured the reduction of phenazepam-associated sedation, attention/memory impairment, and withdrawal-period symptoms, and adds the mechanistic rationale [20] (positive allosteric GABA modulation at a non-benzodiazepine site). The rat gene study [16] is removed from the tolerability anchor here. The parallel "Favorable note" at line 190 was likewise re-anchored from [10][12][16][14] to [10][12][11][14], so its tolerability assertion now also rests on a clinical instrument source rather than the rat study. The single remaining §4 use of [16] (line 164) is legitimate: it is explicitly tagged `mechanism_review` "summarizing the clinical record," and [16] genuinely carries that review-style framing (the same framing it backs at §5 line 213) — so it survives as a review citation, not as primary tolerability data. The claim remains honestly scoped throughout as a single-lineage Russian clinical observation, not a Western-validated finding.

Citation-integrity verification post-edit: bibliography defines [1]–[32] contiguously with no gaps or duplicates; every defined token is used in-body and no token references an undefined entry. No collision or orphan was introduced by the re-anchor. [11] is a pre-existing, already-defined clinical citation (used in §2); no new citation was added to the bibliography.

## Balance / objectivity — PASS
The no-sedation / no-dependence / no-withdrawal differentiator remains consistently scoped as a single-lineage Russian clinical claim, never as Western-established fact. The Abstract calls it "a credible but single-lineage Russian clinical claim that has not been independently replicated in the West." §2 "Integrity scope" instructs the reader to treat it "as a Russian-clinical claim from this single lineage, not as a Western-validated finding." §2 "Honest bottom line" states the absence-of-dependence claim "rests on mechanism ([1]) and lineage assertion rather than on a dedicated human dependence/discontinuation trial." §4 line 190 still hedges with "*if the Russian record holds*." The fix did not introduce any over-crediting; if anything it strengthens objectivity by resting the tolerability claim on the source that actually measured it.

## Unexamined counter-evidence (Doyno & White 2021) — PASS
[19] is genuinely integrated, not name-dropped. The DEFINING FACT flags it as "not a corroborating efficacy study at all but a cautionary pharmacology review." §4 gives it a dedicated paragraph with direct quotes, frames it as "the honest Western counterweight to the Russian 'no dependence' claim," and states it "keeps the dependence question open rather than settled." The dependence question is explicitly held open in §2, §4, and the trial-observed-vs-theoretical split.

## Missing perspective (lineage bias / no Western RCT / no long-term PV) — PASS
Publication/lineage bias is first-class: the DEFINING FACT section, the §3 concentration audit (7/7 ≈100%, 6/7 ≈86% on the strictest reading, with the per-paper table), and the §3 "First-class caveat" surface it as the dominant limitation, correctly noting internal consistency is "the opposite of independent corroboration." Absence of placebo-controlled Western RCTs and of long-term Western pharmacovigilance is stated repeatedly.

## Logical consistency — PASS
§503A reasoning is coherent: Category-2 removal Sept 27 2024 after nomination withdrawal, explicitly "not placement into Category 1," and the 2026 PCAC referral framed as pending "consideration," never "approval." The "RFK Jr Category-1" popular framing is explicitly NOT relied upon. Russia-registered is never conflated with Western-approved. Selank is kept distinct from Semax and from N-Acetyl-Selank-Amidate. WADA S0 reasoning correctly notes the interpretive open question rather than overstating.

Net: the iteration-1 minor citation-precision finding is resolved; the §4 human tolerability claim now rests on clinical/instrument sources [10][12][11] with mechanistic support [20], and the rat study [16] is retained only in its legitimate review role. No new defect introduced; no critical or major defect remains. PASS.

## Verdict
verdict: PASS

```json
{
  "phase": "6",
  "verdict": "PASS",
  "timestamp": "2026-06-21T03:00:00Z",
  "iterations": 2,
  "critique_agent_id": "selank-critic-2",
  "draft_path": "/tmp/aplus-research/selank/synthesis/research-report.md",
  "draft_sha256": "bbf7cd0fcdab76139a4b5a276a3b1d04848de99922ee71897f3c9fe5b6b3226e",
  "findings": [],
  "additional_retrievals": [],
  "halt_reasons": []
}
```
